Clinical Trials Directory

Trials / Completed

CompletedNCT02143531

Intravenous Haloperidol Versus Ondansetron for Treatment of Established Post-operative Nausea and Vomiting

Intravenous Haloperidol Versus Ondansetron for Treatment of Established Nausea and Vomiting in Patients Undergoing Surgery With General Anesthesia: A Randomized Clinical Trial

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
120 (actual)
Sponsor
American University of Beirut Medical Center · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This study aims to prove that at a dose of 1 mg Haloperidol possesses a high success rate in controlling established postoperative nausea and vomiting (PONV) in the first 24 hours following administration similar to the standard of care ondansetron 4 mg.

Detailed description

Patients undergoing surgery under general anesthesia may experience several complications in their postoperative period. Nausea and vomiting are some of the more common of these complications. Several medications can be used for prevention of these specific complications, but treatment remains more cost-efficient. Haloperidol is anti-psychotic which, at low doses, can prevent the occurrence of nausea and vomiting. Its usefulness for prophylaxis has been demonstrated in several studies. However, its use for treating established postoperative nausea and vomiting (PONV) has not been properly studied. In a prospective randomized clinical trial involving adult patients undergoing elective surgery under general anesthesia, investigators will enroll 120 patients, and compare the effect of a dose of 1 mg Haloperidol versus Ondansetron 4 mg and document the varying degrees of success in treating nausea and vomiting as well as possible side effects. Investigators expect to observe that Haloperidol is as effective as treatment with Ondansetron.

Conditions

Interventions

TypeNameDescription
DRUG4 mg of Ondansetron IV
DRUG1mg of Haloperidol IV

Timeline

Start date
2008-09-01
Primary completion
2012-08-01
Completion
2012-08-01
First posted
2014-05-21
Last updated
2014-05-22

Locations

1 site across 1 country: Lebanon

Source: ClinicalTrials.gov record NCT02143531. Inclusion in this directory is not an endorsement.